Hemab Therapeutics Holdings, Inc. (COAG)
41.45
+1.03
(+2.55%)
USD |
NASDAQ |
Oct 30, 16:00
41.45
0.00 (0.00%)
After-Hours: 20:00
Hemab Therapeutics Holdings Debt to Equity Ratio : 0.0023 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0023 |
| Date | Value |
|---|---|
| March 31, 2026 | -1.819 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 467.78M |
| Total Liabilities (Quarterly) | 13.51M |
| Shareholders Equity (Quarterly) | 454.27M |
| Current Ratio | 35.85 |
| Net Debt Paydown Yield | 1.74% |